Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: GH

Guardant Health, Inc.

Healthcare | Medical - Diagnostics & Research

Market prices for GH are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.50

Guardant Health, Inc. (NASDAQ: GH) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 00:23 UTC.

What Guardant Health, Inc. does

Guardant is a precision oncology company that develops blood and tissue tests to help detect cancer early, monitor for recurrence, and guide treatment selection across all stages of cancer care. The company's main products include the Guardant360 CDx test, an FDA-approved comprehensive liquid biopsy for advanced-stage cancer patients; the Shield blood test for colorectal cancer screening; and the Guardant Reveal test for detecting residual disease in early-stage cancer patients.

Summarized from Guardant Health, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.50

Revenue, margins & earnings

FY2021: net loss $385M on revenue $374M$374MFY2021FY2022: net loss $655M on revenue $450M$450MFY2022FY2023: net loss $479M on revenue $564M$564MFY2023FY2024: net loss $436M on revenue $739M$739MFY2024FY2025: net loss $416M on revenue $982M$982MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-15
  • 2026-10-15DirectorSale-69$11.0K
  • 2026-10-13DirectorRestricted Stock UnitsOption exercise-137—
  • 2026-10-13DirectorOption exercise137—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Guardant Health, Inc. do?

Guardant is a precision oncology company that develops blood and tissue tests to help detect cancer early, monitor for recurrence, and guide treatment selection across all stages of cancer care.

When did GH last file with the SEC?

Guardant Health, Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 00:23 UTC. This page is also available as JSON at /api/data?ticker=GH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for GH and 5,000+ tickers.

Create a free account — keep GH
For your agent
GET /api/data?ticker=GH

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt